Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Biodiversity Loss and Climate Change: Understanding the Feedback Loop
- 2 Concentration of Exports in Developed States: Implications for Inclusive Growth
- 3 Bioremediation: Answer to India’s Solid Waste Challenge
- 4 Decoding Regulations and Structural Gaps in India’s Civil Aviation Sector
- 5 India’s Biosecurity Imperatives: Securing Health and the Nation
- 6 From Solar Power to Solar Waste: India’s Emerging Concern
- 7 India-Oman CEPA: A Strategic Reset in the Gulf
- 8 Transforming India into a Leading Quantum-Powered Economy
- 9 Inhalable Microplastics: India’s Emerging Health Threat
- 10 NFSI 2025-30: Accelerating Equitable Financial Prosperity
